Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 21,712	$ 28,918
Prepaid expenses and other current assets	1,298	593
Total Current Assets	23,010	29,511
Property and equipment, net	485	607
Right of Use Asset	481	0
Deposits and other assets	23	23
Total Assets	23,999	30,141
Current Liabilities:
Accounts payable	1,523	1,034
Accrued expenses	1,544	919
Accrued employee benefits	511	1,332
Deferred rent	0	99
Lease liability	233	0
Total Current Liabilities	3,811	3,384
Long term deferred rent	0	302
Lease liability - Long term	601	0
Total Liabilities	4,412	3,686
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding	12,419	12,296
Stockholders' Equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 16,647,888, issued and 16,645,560 outstanding and 15,484,411, issued and 15,482,083 outstanding	17	15
Additional paid-in capital	232,211	230,754
Accumulated deficit	(227,141)	(219,461)
Total Synthetic Biologics, Inc. and Subsidiaries Equity	10,022	17,068
Non-controlling interest	(2,854)	(2,909)
Total Stockholders' Equity	7,168	14,159
Total Liabilities and Stockholders' Equity	23,999	30,141
Series B Preferred Stock [Member]
Stockholders' Equity:
Series B Convertible Preferred stock, $1,000 par value; 10,000,000 shares authorized, 7,823 issued and outstanding and 9,161 issued and outstanding	4,935	5,760
Total Stockholders' Equity	$ 4,935	$ 5,760